DOCSLIB.ORG

Diapositiva 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Diapositiva 1 New treatment options for sleep disorders Chairs: Gabriella Gobbi and Anton Y. Bespalov . Novel selective melatonin MT2 receptor agonist in the treatment of insomnia . Gabriella Gobbi, Canada . Orexin receptor antagonists and insomnia treatment: state of the art . Anthony Gotter, US . Development of piromelatine, a novel multimodal sleep medicine . Nava Zisapel, Israel . The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders Abstract . Jian Sheng Lin , France Prevalence insomnia in Canada and Europe Canadian survey1 European survey2 on sleep and related factors on insomnia and sleep symptoms (N=2000) (N=25,579) 50 50 40.4% 40 40 34.5% 30 30 Respondents (%) Respondents (%) 20 20 13.4% 9.8% 10 10 0 0 Insomnia symptoms Insomnia disorder Insomnia symptoms Insomnia disorder 1. Morin et al. Can J Psychiatry. 2011;56:540-548; 2. Ohayon et al. Sleep Med. 2009;10:952-960. Prevalence in the American Insomnia Survey . 10,094 members of a managed health care plan . Prevalence 23.6%* . Insomnia symptoms: about 45% . Risk of insomnia higher in: . Women vs men . Older age vs younger groups (18-64 vs >65 y) . Disabled or retired vs employed . Shift workers vs day workers . Obese vs normal BMI Diagnosis based on any one of 3 systems: DSM-IV-TR, ICD-10, RDC/ICSD-2. *Insomnia assessed using Brief Insomnia Questionnaire (BIQ). Roth et al. Biol Psychiatry. 2011;69:592-600. Insomnia and Societal Burden •Increased risks of depression and alcohol Psychiatric dependence1,2 •Increased risks of hypertension, metabolic Health syndrome, and coronary heart disease2 •Decreased productivity and increased Occupational absenteeism1,2 Economic •Increased health care costs1,2 Public safety •Increased risks of accidents1 1. Léger, Bayon. Sleep Med Rev. 2010;14:379-389; 2. Buysse. JAMA. 2013;309:706-716. DRUG DISCOVERY FOR SLEEP DISORDERS 2014 2005 1986 Orexin antagonists 1960 MLT agonist Benzodiazepine- Ramelteon (US) derivates 1903 Benzodiazepines (zopiclone) Circadin (EU) (chlordiazepoxide) 1869 Barbiturates Chloral Hydrate 600 BC: Alcohol as therapeutics Important need of novel targets and novel drug discovery Novel selective melatonin MT2 partial agonists for the treatment of insomnia Gabriella Gobbi, MD, PhD Neurobiological Psychiatry Unit Department of Psychiatry, McGill University Montréal, Canada Sleep Stages: EEG Features1,2 NREM REM Wakefulness Light sleep Light sleep Deep SWS REM stage 1 stage 2 stage 3 & 4 • Rapid eye movement • Transitional stage • Light sleep (REM) • Similar to drowsy waking • Low muscle tone, slow • Slow-wave sleep (SWS) • Muscle atonia • High muscle tone rolling eye movements • Active dreams EEG activity: EEG activity: • Rate & variability EEG activity: EEG activity: • Frequency begins • Strong delta of autonomic nervous • Low voltage fast activity to slow • Sleep spindles (0.5–4 Hz) activity system function in the beta range (7–14 Hz) and (15–30 Hz) • Alpha (8–14 Hz) activity K-complexes • Large amplitude EEG activity: mostly at posterior sites increases • Frequency slows to the • Returns to profile similar theta range (4–8 Hz) to wakefulness (low voltage fast activity) 1. Iber et al. AASM manual for the scoring of sleep and associated events. http://www.aasmnet.org/scoringmanual/default.aspx; 2. Brown et al. Physiol Rev. 2012;92:1087-1187. Visualizing Sleep Quantity and Quality Hypnograms showing distribution of normal sleep pattern1 Schematic representation Normal subject Over the course of normal sleep, SWS and REM sleep alternate cyclically2 1. Gander. Sleep in the 24-Hour Society. Lower Hutt, NZ: The Open Polytechnic of New Zealand, 2003; 2. Colten, Altevogt, eds. Sleep Disorders and Sleep Deprivation. 2006; www.nap.edu. Common Wisdom: Melatonin and sleep Melatonin & sleep: Clinical Melatonin (N-acetyl-5-methoxytryptamine, MLT), synthesized by the pineal gland, has been reported to have hypnotic effects in humans, although results are still controversial (Brzezinski et al., 2005; Buscemi et al., 2006). Controversial studies on the role of melatonin in sleep, even if there is a concordance on the soporific effect and sleep-inducing effects of melatonin. Melatonin & sleep: Animal Animal studies have demonstrated that MLT reduces time to sleep onset and increases both NREMS and REMS (Holmes and Sugden, 1982; Mirmiran and Pevet, 1986), both effects being blocked by the GABAA receptor antagonists flumazenil and picrotoxin (Wang et al., 2003a). Other studies showed little or no effect (Mailliet et al., 2001; Wang et al., 2003). Melatonin and its receptors c-AMP MT1 receptor PIP-2 MLT1a c-AMP PIP-2 MT2 receptor MLT1b Guanylyl cyclase Dubocovich et al., Pharm Reviews , 2010 MT1 and MT2 in sleep Which receptor is involved in sleep? Lack of sleep studies using selective MT1 or MT2 ligands Lack of sleep studies in MT1KO and MT2KO. Ligand-model provides 3D-QSAR and SAR analysis based on 100s of compounds 3D-QSAR Agonist model pharmacophore Purple: rhodopsin Rivara S. et al., J. Med. Chem. 2005, 48, 4049 Green: MT2 Spadoni G.et al. J. Med. Chem. 1997, 40, 1990 Mor M. et al. J. Med. Chem. 1998, 41, 3831 Orange MT2 TM5 UCM765 and UCM924: novel MT2 selective partial agonists Pro-Lead Compound Lead Compound UCM 765 UCM 924 N-{2-[(3-methoxyphenyl)phenylamino]ethyl}acetamide N-{2-[(3-bromophenyl)-(4-fluorophenyl)amino]ethyl}acetamide N-(Substituted-anilino-ethyl)amides Rivara et al., JMC, 2007 Rivara et al., CMC, 2009 UCM765 and UCM924: novel MT2 selective partial agonists PRO-LEAD LEAD UCM-765 UCM-924 8.38 6.75 MT1 (pKi) Partial agonist Antagonist 10.18 10.2 MT2 (pKi) Partial agonist Partial agonist 6.3 (23.7% F% (p.o) 0.9 oral formulation) 44 IV 39 IV T1/2 (min) 68 PO Rivara et al., 2007, 2009 UCM765 SLEEP RECORDING Effects of UCM765 on sleep parameters NREM NREM Latency Total time +48% 30 450 * * * 25 400 350 20 -59% 300 250 15 * * 200 10 150 100 Light phase 5 50 Dark phase 0 0 Veh 20 40 60 Veh 20 40 60 UCM765 (mg/kg, s.c.) UCM765 (mg/kg, s.c.) REM Wakefulness Total time Total time 100 600 90 500 80 70 400 60 * 50 300 * * * 40 200 30 Light phase Light phase 20 100 Dark phase Dark phase 10 0 0 Veh 20 40 60 Veh 20 40 60 UCM765 (mg/kg, s.c.) UCM765 (mg/kg, s.c.) Ochoa-Sanchez et al., J.Neuroscience, 2011 UCM765 (40 mg/kg) on NREM sleep 24 hours analysis Ochoa-Sanchez et al., J.Neuroscience, 2011 LEAD COMPOUND UCM924 SLEEP RECORDING COMPARISON WITH MELATONIN AND NON- SELECTIVE MT1-MT2 UCM924, MLT and UCM793 (40 mg/kg) on NREM sleep 24 hours analysis VEH UCM924 (40 mg/kg) MELATONIN (40 mg/kg) UCM793 (40 mg/kg) Ochoa-Sanchez et al, Neuroscience Letters 201421 MLT, UCM793, UCM924, 24 hours analysis (total Time) Latency NREM REM Wake to sleep fullness MLT δ Non- selective MT1-MT2 MT2 δ selective Ochoa-Sanchez et al, Neuroscience Letters 2014 Immunocytochemical localization of MT2 receptors Reticular Thalamus Ochoa-Sanchez et al., J.Neuroscience, 2011 Reticular thalamic neurons NREM/SWS State-dependent activity in thalamic and cortical neurones (from Steriade et al., 1993) Hypothesis If MT2 receptors are located in the Rt nuclei, the UCM765 should be able to activate these neurons Electrophysiological in vivo recording in reticular thalamic neurons DIFFERENTIAL AMPLITUDE DISCRIMINATOR UCM765 increases firing and burst activity of reticular thalamic neurons MT2 ANTAGONIST 4P-PDOT The effect of the partial agonist is blocked by the antagonist H3CH2COCHN MT2 receptors (pKi = 8.8) MT1 receptors (pKi = 6.3) (Dubocovic et al., 1997) Microinfusion into the reticular thalamic neurons of the MT2 antagonist 4P-PDOT. 4P-PDOT prevents the UCM 765 from increasing firing and burst activity Conclusion 1 The pharmacological activation of MT2 receptors promotes sleep, in particular NREM or SWS and decrease the latency to sleep Melatonin decreases the latency to sleep but not sleep duration The MT2 receptors are localized in the reticular thalamus, and they promote NREM through the rhythmic and burst activation of reticular thalamic neurons, which is the hallmark of NREM/SWS. The MT2 receptor represents a novel target for hypnotics Sleep recording in MT1, MT2 and MT1-MT2 knockout mice C3H Sleep recording in MT1, MT2 and MT1-MT2knockout mice 24 h sleep-wake analysis Comai et al., Behavior Brain Res, 2013 NREM NREM decreased in MT2 KO , but increased in MT1 KO 4 second period analysis 10 second period analysis NREM sleep Total time Total time 450 450 400 400 350 350 ) 300 ) 300 n n i i m 250 m ( ( 250 e 200 e m m 200 i i T 150 T 150 100 100 50 50 0 0 WT MT -/- MT -/- MT -/-MT -/- WT MT -/- MT -/- MT -/-MT -/- -/- -/- -/- -/- -/- -/- -/- -/- 1 2 1 2 1 2 1 2 WT MT1 MT2 MT1 MT2 WT MT1 MT2 MT1 MT2 Light Dark Light Dark Comai et al., Behavior Brain Res, 2013 NREM sleep in MT1, MT2 and MT1- MT2knockout mice: NREM decreases in MT2 KO (light) Comai et al., Behavior Brain Res, 2013 Opposite effects of MT1 and MT2 receptors in NREM MT2 MT1 NREM REM REM decreases only in MT1 KO Blunted light-dark difference in MT1 KO 4 second period analysis 10 second period analysis REM sleep 120 Total time 120 Total time 100 no light/dark difference 100 80 80 ) ) n n no light/dark difference i i m m ( 60 ( 60 e e m m i i T 40 T 40 20 20 0 0 -/- -/- -/- -/- -/- -/- -/- -/- -/- -/- -/- -/- -/- -/- -/- -/- WT MT1 MT2 MT1 MT2 WT MT1 MT2 MT1 MT2 WT MT1 MT2 MT1 MT2 WT MT1 MT2 MT1 MT2 Light Dark Light Dark Comai et al., Behavior Brain Res, 2013 REM sleep in MT1, MT2 and MT1- MT2 knockout mice: REM decreases only in MT1 KO Comai et al., Behavior Brain Res, 2013 Differential role of receptors NREM REM WAKEFULNESS MT1 knockout * MT2 knockout MT1-MT2 knockout (24) * 10 sec analysis Comai et al., 2013 Conclusion 2 The MT1 and MT2 receptor have a differential role in sleep regulation, this role could explain the relative low effect of non-selective MT1-MT2 agonist, including melatonin, and the lack of significant sleep impairment in double MT1- MT2 knockout Genetic and pharmacological manipulation of MT2 receptor has confirmed the selective implication of this receptor in NREM Pharmacological activation of melatonin MT2 receptors NREM Acknowledgments Gabriella Gobbi’s lab Pharmacology and antibodies, Immunohisto EEG/EMG & Electrophysiology, • Franco Fraschini (Univ.
Load more

Recommended publications
  • Neuroscience Product Handbook
    www.MedChemExpress.com MedChemExpressMedChemExpress Neuroscience Product Handbook Pain Biological Rhythms and Sleep Neuromuscular Diseases AutonomicNeuroendocrine Somatosensation metabolism Regulation Processes transduction Behavioral Neuroethology Neuroendocrin feature soding Food Intake oral and speech From the itineraries of and Energy Balance vocal/social 8,329 attendees Touch Thirst and communication Water Balance social behavior Development peptides at the 2018 SfN meeting Ion Channels and Evolution Stress and social cognition opiates the Brain monoamines Spinal Cord Adolescent Development PTSD Injury and Plasticity Postnatal autism Developmental fear Neurogenesis Disorders human social Mood cognition ADHD, Disorders Human dystexia Anxiety Cognition and Neurogenesis depression Appetitive Behavior and Gllogenesis bipolar and Aversive timing Development of Motor, Schizophrenia Learning perception Sensory,and Limbic Systems perceptual learning Other Psychiatric executive attention Stem Cells... mitochondria Emotionfunction human Parkinson's Glial Mechanisms biomarkers reinforcement long-term Disease Synaptogenesis human human memory Huntington's Transplant and ... Development Neurotransm., Motivation decisions working and Regen Axon and Transportors, memory PNS G-Protein...Signaling animal Dendrite reward decision visual Other Movement Development Receptors learning and memory model microglia making decisions Disorders Demyelinating NMDA dopamine ataxia Disorders place cells, GABA, LT P Synaptic grid cells gly... Plasticity striatum
    [Show full text]
  • Sleep Disorders & Medicine
    Nava Zisapel et al., J Sleep Disord Ther 2015, 4:4 http://dx.doi.org/10.4172/2167-0277.S1.002 Annual Summit on Sleep Disorders & Medicine August 10-12, 2015 San Francisco, USA Piromelatine: A novel melatonin-serotonin agonist for the treatment of insomnia disorder and neurocognitive comorbidities Nava Zisapel1 and Moshe Laudon2 1Tel Aviv University, Israel 2Neurim Pharmaceuticals Ltd., Israel nsomnia affects 30%-50% of the general population and even more so (63%) among patients with mild cognitive impairments I(MCI). Alzheimer’s disease (AD) risk among insomnia patients is approximately 3 fold that of good sleepers. Furthermore, poor sleep quality is associated with faster cognitive decline and may be an early marker of cognitive decline in mid life. Improvement of sleep may be critically important for maintaining or enhancing cognitive function in patients with MCI or AD. Current hypnotic medications (benzodiazepines and benzodiazepines-like) are associated with cognitive and memory impairments, increased risk of falls, accidents and dependency. Melatonin receptors agonists are safe and effective drugs for primary insomnia and circadian rhythm sleep disorders and are potentially useful for cognition and sleep in. Piromelatine is a novel investigational MT1\MT2 and 5HT1A\D receptors agonist developed for primary and co-morbid insomnia. In Phase-I studies it demonstrated good oral bioavailability (Elimination half-life 2.8±1.4 hours), good safety & tolerability profile across a wide dose range and provided the first indication for beneficial effects on sleep maintenance. In a Phase-II study in insomnia patients, piromelatine demonstrated significant improvements in sleep maintenance based on objective assessments (polysomnography recorded wake after sleep onset, sleep efficiency and total sleep time) and good safety profile with no detrimental effects on next-day psychomotor performance and memory.
    [Show full text]
  • Melatonin Receptor Agonist Piromelatine Ameliorates Impaired Glucose Metabolism in Chronically Stressed Rats Fed a High-Fat Diet
    1521-0103/364/1/55–69$25.00 https://doi.org/10.1124/jpet.117.243998 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 364:55–69, January 2018 Copyright ª 2017 by The American Society for Pharmacology and Experimental Therapeutics Melatonin Receptor Agonist Piromelatine Ameliorates Impaired Glucose Metabolism in Chronically Stressed Rats Fed a High-Fat Diet Jun Zhou, Deng Wang, XiaoHong Luo, Xu Jia, MaoXing Li, Moshe Laudon, RuXue Zhang, and ZhengPing Jia College of Pharmacy, Lanzhou University, Lanzhou, PR China (J.Z., M.X.L, R.X.Z, Z.P.J.); Xi’an Daxing Hospital, Shaanxi, PR China (D.W.); Lanzhou General Hospital of PLA, Lanzhou, PR China (J.Z., X.L., M.X.L, R.X.Z, Z.P.J.); Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China (X.J.); and Drug Discovery, Neurim Pharmaceuticals Ltd., Tel-Aviv, Israel (M.L.) Downloaded from Received July 19, 2017; accepted October 6, 2017 ABSTRACT Modern lifestyle factors (high-caloric food rich in fat) and daily combined with CS (CF). The results showed that piromelatine chronic stress are important risk factors for metabolic distur- prevented the suppression of body weight gain and energy jpet.aspetjournals.org bances. Increased hypothalamic-pituitary-adrenal (HPA) axis intake induced by CF and normalized CF-induced hyperglycemia activity and the subsequent excess production of glucocorticoids and homeostasis model assessment–IR index, which suggests (GCs) in response to chronic stress (CS) leads to increases in that piromelatine prevented whole-body IR. Piromelatine also metabolic complications, such as type 2 diabetes and insulin prevented CF-induced dysregulation of genes involved in resistance (IR).
    [Show full text]
  • Blood Pressure Reducing Effects of Piromelatine and Melatonin in Spontaneously Hypertensive Rats
    Eur opean Rev iew for Med ical and Pharmacol ogical Sci ences 2013; 17: 2449-2456 Blood pressure reducing effects of piromelatine and melatonin in spontaneously hypertensive rats L. HUANG 1,2 , C. ZHANG 1, Y. HOU 1, M. LAUDON 4, M. SHE 3, S. YANG 3, L. DING 3, H. WANG 2, Z. WANG 5, P. HE 1, W. YIN 1,3 1Institute of Cardiovascular Research, Key Laboratory for Arteriosclerosis of Hunan Province, University of South China, Hengyang, Hunan, People's Republic of China, China 2Department of Operative Surgery, University of South China, Hengyang, Hunan, People's Republic of China, China 3Department of Biochemistry and Molecular Biology, School of Life Sciences and Technology, University of South China, Hengyang, Hunan, People's Republic of China, China 4Drug discovery, Neurim Pharmaceuticals Ltd, Tel-Aviv, Israel 5Department of Laboratory Animal Science, University of South China, Hengyang, Hunan, People's Republic of China, China Abstract. – BACKGROUND : Recently, wide - Key Words: spread interest has grown regarding melatonin Piromelatine, Melatonin, Hypertension, Sponta - treatment of hypertension including its cardiopro - neously hypertensive rats, Metabolic diseases. tective effects. Studies in rodents indicate that melatonin plays a role in the pathogenesis of hy - pertension in rats with metabolic syndrome. Piromelatine, a melatonin agonist, serotonin Introduction 5-HT-1A and 5-HT-1D agonist and serotonin 5- HT2B antagonist is a multimodal agent with sleep promoting, anti-diabetic, analgesic, anti- The pineal hormone melatonin is secreted with neurodegenerative, anxiolytic and antidepres - a marked circadian rhythm. The endogenous sant potential, currently in development for the rhythm of secretion is generated by the suprachi - treatment of insomnia.
    [Show full text]
  • Product Data Sheet
    Inhibitors Product Data Sheet Piromelatine • Agonists Cat. No.: HY-105285 CAS No.: 946846-83-9 Molecular Formula: C₁₇H₁₆N₂O₄ • Molecular Weight: 312.32 Screening Libraries Target: Melatonin Receptor; 5-HT Receptor; P2X Receptor; TRP Channel; Sodium Channel Pathway: GPCR/G Protein; Neuronal Signaling; Membrane Transporter/Ion Channel Storage: 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) SOLVENT & SOLUBILITY In Vitro DMSO : 250 mg/mL (800.46 mM; Need ultrasonic) Mass Solvent 1 mg 5 mg 10 mg Concentration Preparing 1 mM 3.2018 mL 16.0092 mL 32.0184 mL Stock Solutions 5 mM 0.6404 mL 3.2018 mL 6.4037 mL 10 mM 0.3202 mL 1.6009 mL 3.2018 mL Please refer to the solubility information to select the appropriate solvent. In Vivo 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (6.66 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (6.66 mM); Clear solution BIOLOGICAL ACTIVITY Description Piromelatine (Neu-P11) is a melatonin MT1/MT2 receptor agonist, serotonin 5-HT1A/5-HT1D agonist, and serotonin 5-HT2B antagonist. Piromelatine (Neu-P11) possesses sleep promoting, analgesic, anti-neurodegenerative, anxiolytic and antidepressant potentials. Piromelatine (Neu-P11) also possesses pain-related P2X3, TRPV1, and Nav1.7 channel-inhibition capacities[1][2][3]. IC₅₀ & Target MT1 MT2 5-HT1A Receptor 5-HT1D Receptor (Agonist) (Agonist) 5-HT2B Receptor (Antagonist) Page 1 of 3 www.MedChemExpress.com In Vivo Piromelatine (20 mg/kg, ip, daily) treatment prevents insulin resistance induced by sleep restriction[1].
    [Show full text]
  • Focus on Metabolism and Chronobiology
    Focus Sci. Review Article Feb 2016, Volume 2, Issue 1 Melatonergic Treatment: Focus on Metabolism and Chronobiology Rüdiger Hardeland 1, * 1 Johann Friedrich Blumenbach Institute of Zoology and Anthropology, University of Göttingen, Göttingen, Germany * Corresponding author: Johann Friedrich Blumenbach Institute of Zoology and An- thropology, University of Göttingen, Berliner Str. 28, D-37073 Göttingen, Germany. Tel: +49-551395414. E-mail: [email protected] Submitted: 01.10.2016 Abstract Accepted: 02.12.2016 Introduction: Melatonin is produced in various organs, but its preferentially nocturnal synthesis and release by the pineal gland is decisive for its chronobiological actions. Keywords: The short half-life of circulating melatonin has been reason for developing synthetic Agomelatine melatonergic agonists. With regard to age- and disease-related dysfunction of the Circadian melatonergic system, treatment with melatonin or its synthetic analogs may be used for Melatonin alleviating health problems with a respective etiology. This review addresses limitations Kynuramine arising from drug-specific metabolism and disregarded chronobiological rules. Ramelteon Metabolism: Differences are illustrated by comparing the metabolism of melatonin and two approved synthetic melatonergic agonists, ramelteon and agomelatine. Apart from © 2016. Focus on Sciences hydroxylation and dealkylation reactions, melatonin can be converted to methoxylated kynuramines, a route absent in the two synthetic drugs. An unsual property is present in the ramelteon metabolite M-II, which still displays melatonergic activity, but attains 30 to 100 times higher levels than the parent compound. Two double-hydroxylated agomelatine metabolites may be involved in sometimes occurring hepatotoxicity. Chronobiology of Melatonergic Drugs: Sleep latency facilitation and readjustment of circadian rhythms require only short actions.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • A Novel Neuroregenerative Approach Using ETB Receptor Agonist, IRL-1620, to Treat CNS Disorders
    Physiol. Res. 67 (Suppl. 1): S95-S113, 2018 https://doi.org/10.33549/physiolres.933859 REVIEW A Novel Neuroregenerative Approach Using ETB Receptor Agonist, IRL-1620, to Treat CNS Disorders A. GULATI1*, M. G. HORNICK1*, S. BRIYAL1*, M. S. LAVHALE2 *These authors contributed equally to this article. 1Chicago College of Pharmacy, Midwestern University, Downers Grove, IL, USA, 2Pharmazz Research Center, Pharmazz India Private Limited, Greater Noida, UP, India Received January 15, 2018 Accepted April 17, 2018 Summary Introduction Endothelin B (ETB) receptors present in abundance the central nervous system (CNS) have been shown to have significant Endothelin (ET), an endogenous 21 amino acid implications in its development and neurogenesis. We have peptide, was first isolated from porcine aortic endothelial targeted ETB receptors stimulation using a highly specific agonist, cells nearly 3 decades ago (Yanagisawa et al. 1988). IRL-1620, to treat CNS disorders. In a rat model of cerebral There are 3 distinct isopeptides: ET-1, ET-2, and ET-3 ischemia intravenous administration IRL-1620 significantly which are present in various mammalian tissues reduced infarct volume and improved neurological and motor performing a myriad of physiological and pathological functions compared to control. This improvement, in part, is due roles such as regulation of blood pressure and perfusion, to an increase in neuroregeneration. We also investigated the apoptosis and cellular proliferation and migration role of IRL-1620 in animal models of Alzheimer’s disease (AD). (Ehrenreich et al. 2000, Inoue et al. 1989, Vidovic et al. IRL-1620 improved learning and memory, reduced oxidative 2008, Yanagisawa et al. 1988). The ET peptides produce stress and increased VEGF and NGF in Aβ treated rats.
    [Show full text]
  • A Crosstalk Between Melatonin and Taste-Receptors' Signaling Tunes Quinine-Induced Gut Hormone Secretion in Mice
    ition & F tr oo u d N f S o c Tenore et al., J Nutr Food Sci 2018, 8:1 l i e a n n r c DOI: 10.4172/2155-9600.1000664 e u s o J Journal of Nutrition & Food Sciences ISSN: 2155-9600 Research Article Open Access A Crosstalk between Melatonin and Taste-Receptors’ Signaling Tunes Quinine-Induced Gut Hormone Secretion in Mice Gian Carlo Tenore, Sara Bottone, Gennaro Riccio, Nadia Badolati, Mariano Stornaiuolo* and Ettore Novellino Department of Pharmacy, University of Naples Federico II, Via Montesano 49, 80138 Naples, Italy Abstract Quinine consumption has been shown to reduce appetite and food intake in human and mice. Here, tested on two common mouse strains, C3H/lbg and C57BL/6J, it exerted a different effect. While quinine reduced weight gain in C3H/lbg mice, C57BL/6J were unaffected by the bitter molecule. Among the differences between the two strains, C57BL/6J present a blunted Melatonin production. In this study, we investigate if endogenous Melatonin is playing any role in the different response of C57BL/6J mice to quinine. The effect of dietary supplementation with Melatonin as well as of endogenous gastrointestinal and pineal produced Melatonin was investigated by supplementing quinine diet with pure Melatonin, L-Tryptophan or by reversion of light/dark cycle, respectively. The consumption of Melatonin reverts the phenotype and makes C57BL/6J mice sensitive to quinine. Similarly, quinine potency in C3H/ Ibg mice augments upon supplementation with exogenous Melatonin or upon increase of Melatonin endogenous levels. In vivo, as well as in in vitro cell cultures, Melatonin Receptor modulation inhibits quinine dependent secretion of Ghrelin, while potentiates quinine dependent secretion of Cholecystokinin.
    [Show full text]
  • Inflammaging, Metabolic Syndrome and Melatonin: a Call for Treatment Studies
    Cardinali, Daniel P. ; Hardeland, Rüdiger Inflammaging, metabolic syndrome and melatonin: a call for treatment studies Preprint del documento publicado en Neuroendocrinology Vol. 104, N° 4, 2017 Este documento está disponible en la Biblioteca Digital de la Universidad Católica Argentina, repositorio institucional desarrollado por la Biblioteca Central “San Benito Abad”. Su objetivo es difundir y preservar la producción intelectual de la Institución. La Biblioteca posee la autorización de los autores y de la editorial para su divulgación en línea. Cómo citar el documento: Cardinali DP, Hardeland R. Inflammaging, metabolic syndrome and melatonin : a call for treatment studies [en línea]. Preprint del documento publicado en Neuroendocrinology 2017;104(4):982-392. doi: 10.1159/000446543. Disponible en: http://bibliotecadigital.uca.edu.ar/repositorio/investigacion/inflammaging-metabolic-syndrome-melatonin.pdf [Fecha de consulta: ….] Publicado en Neuroendocrinology 104(4):382-397; 2017 Inflammaging, Metabolic Syndrome and Melatonin: A Call for Treatment Studies Daniel P. Cardinali a, Rüdiger Hardeland b a BIOMED-UCA-CONICET and Department of Teaching and Research, Faculty of Medical Sciences, Pontificia Universidad Católica Argentina, 1107 Buenos Aires, Argentina b Johann Friedrich Blumenbach Institute of Zoology and Anthropology, University of Goettingen, Berliner Str. 28, D-37073 Goettingen, Germany Running title: Melatonin and the Metabolic Syndrome Key Words: Melatonin – Metabolic syndrome – Inflammation – Diabetes – Obesity - Insulin signaling
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Melatonin in the Gastrointestinal Tract
    Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1616 Melatonin in the gastrointestinal tract FANNY SÖDERQUIST ACTA UNIVERSITATIS UPSALIENSIS ISSN 1651-6206 ISBN 978-91-513-0814-2 UPPSALA urn:nbn:se:uu:diva-396347 2019 Dissertation presented at Uppsala University to be publicly examined in Humanistiska teatern, Thunbergsvägen 3, Uppsala, Friday, 17 January 2020 at 09:00 for the degree of Doctor of Philosophy (Faculty of Medicine). The examination will be conducted in Swedish. Faculty examiner: Professor Bodil Ohlsson (Lunds Universitet). Abstract Söderquist, F. 2019. Melatonin in the gastrointestinal tract. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1616. 63 pp. Uppsala: Acta Universitatis Upsaliensis. ISBN 978-91-513-0814-2. Melatonin is recognised as the pineal hormone regulating sleep and circadian rhythm. It has also been identified in peripheral tissues (mainly in animals) and thought to display a variety of actions, including anti-inflammatory properties, regulation of gastrointestinal (GI) functions, glucose homeostasis and beneficial effects in different tumour types. Patients with irritable bowel disorder commonly exhibit psychiatric co-morbidity and disturbances of the gut-brain axis have been proposed to play a role in these disorders. The focus of this thesis was to study melatonin and melatonin receptors in the normal human GI tract, the pancreas and small intestinal neuroendocrine tumours. The thesis also explores the complex relationship between GI symptoms and underlying psychiatric traits in the context of elevated levels of peripheral melatonin during waking hours. In paper I-II, tissue samples from the normal human GI tract and pancreas and tumour tissue from small intestinal neuroendocrine tumours were analysed for expression of melatonin and melatonin receptors using immunohistochemistry.
    [Show full text]